Skip Navigation

JNCI Journal of the National Cancer Institute 1993 85(22):1844-1850; doi:10.1093/jnci/85.22.1844
© 1993 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pujol, J.-L.
Right arrow Articles by Jett, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pujol, J.-L.
Right arrow Articles by Jett, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 85, No. 22, 1844-1850, November 17, 1993
© 1993 Oxford University Press

Immune Response Induced in Small-Cell Lung Cancer by Maintenance Therapy With Interferon {gamma}

Jean-Louis Pujol, Donna Jean Gibney, John Q. Su, Andrew W. Maksymiuk, James R. Jett

University of Montpellier and School of Medicine, Chest Department, Hópital Arnaud de Villeneuve Montpellier, France
North Central Cancer Treatment Group and Mayo Clinic Rochester, Minn.

Correspondence to: James R. Jett, M.D., Mayo Clinic, Division of Medical Oncology, East 18, 200 First St., SW, Rochester, MN 55905

Background: Chemotherapy, with or without radiotherapy, results in a 30%–40% complete response rate in small-cell lung cancer (SCLC), but approximately 90% of patients who have complete remission die within 2 years after relapse with chemoresistant disease. Randomized clinical studies of maintenance chemotherapy after complete response have failed to demonstrate survival advantage. However, studies have shown that the human cytokine interferon {gamma} (IFN-{gamma}) induces immune response in humans, including T-cell activation and expression of class II major histocompatibility complex (HLA-DR) and receptor for the Fc portion of immunoglobulin on monocytes. It has also been demonstrated that recombinant IFN-{gamma} (rIFN-{gamma}) induces immunomodulation and has antiproliferative activity. Purpose: In vivo effects of rIFN-{gamma} treatment were characterized by flow cytometric analysis of peripheral blood mononuclear cells in patients with SCLC who received rIFN-{gamma}; as maintenance treatment. Methods: After induction chemotherapy and radiotherapy, 100 patients who achieved a complete remission were randomly assigned to receive rIFN-{gamma}; at a dose of 0.2 mg (4 x 106 units) once a day, subcutaneously, for 6 months, or observation only. In 31 patients, peripheral mononuclear cells were obtained prior to the study and at weeks 4, 8, and 12 for serial monitoring of immune response. By flow cytometric analysis, we identified the lymphocyte and monocyte populations using characteristic differences in electronic volume and right-angle scatter. In these populations, we determined the mean fluorescence channel after staining for CD14 (antigen expressed on monocytes), CD3 (antigen expressed on T lymphocytes), and HLA-DR (HLA class II expressed by monocytes and activated lymphocytes). To determine the number of Fc receptors per cell, an Fc receptor assay was performed using the monocyte cell line U937 as a standard. Results: At weeks, 4, 8, and 12, expression of HLA-DR and Fc receptors on monocytes in patients who received rIFN-{gamma}; was significantly higher than that in untreated patients, and the difference was statistically significant. The number of Fc receptors per monocyte consistently increased during the rIFN-{gamma}; treatment and reached a fivefold elevation at week 12. There was no statistically significant difference in lymphocyte surface antigen expression between the treated and untreated groups. Conclusion: The dose of rIFN-{gamma}; used in this study resulted in immune stimulation in patients with SCLC who had complete remission after induction therapy. The in vivo immuno-modulatory activity of rIFN-{gamma}; in such patients is characterized by a strong monocyte activation but no significant alteration in T-cell activation. [J Natl Cancer Inst 85:1844–1850, 1993]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. L. Pujol, J. L. Breton, R. Gervais, M.-L. Tanguy, E. Quoix, P. David, H. Janicot, V. Westeel, S. Gameroff, J. Geneve, et al.
Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04 IFCT 00-01
J. Clin. Oncol., September 1, 2007; 25(25): 3945 - 3951.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Giaccone, C. Debruyne, E. Felip, P. B. Chapman, S. C. Grant, M. Millward, L. Thiberville, G. D'addario, C. Coens, L. S. Rome, et al.
Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
J. Clin. Oncol., October 1, 2005; 23(28): 6854 - 6864.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.